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Oryeongsan (ORS), a traditional medicine used to regulate body fluids, has a long history of use as a diuretic in Korea, China, and
Japan. ORS is commonly thought to lower blood pressure, but high-quality data on its effects are sparse. .e purpose of this study
was to determine the antihypertensive and renal protective effects of ORS in rats with hypertension. Spontaneously hypertensive
rats (SHR) were divided into two groups with similar mean baseline systolic blood pressure (SBP) and diastolic blood pressure
(DBP). .en, 10mL/kg of vehicle (distilled water) or 200mg/kg of ORS extract were administered orally once a day for 3 weeks.
SBP andDBPweremeasured at weeks 1, 2, and 3. At the end of the experiment, blood was collected, and kidneys were removed for
histology. By the 2nd and 3rd week after initiation of treatment, the ORS-treated group had significantly lower SBP than control-
treated rats (191.3± 6.5 vs. 206.3± 9.8mmHg, p � 0.022 at the 2nd week; 195.8± 7.8 vs. 217.0± 8.1mmHg, p � 0.003 at the 3rd
week, respectively). .e ORS-treated group trended toward having a lower DBP than control, but there was no significant
difference. Blood urea nitrogen (BUN) and serum creatinine (Cr) were not different between the ORS-treated and control groups
(BUN: 23.7± 1.1 vs. 22.7± 2.8mg/dL, p � 0.508; Cr: 19.0± 2.2 vs. 21.6± 2.1 μM, p � 0.083, respectively). .e percentage of renal
tissue affected by tubulointerstitial fibrosis was significantly lower in the ORS-treated group (1.68± 0.60) compared to controls
(3.17± 0.96, p � 0.019). .ese findings suggest that treatment with ORS reduces SBP and ameliorates renal damage in SHR.
1. Introduction
Hypertension is a leading risk factor of death from car-
diovascular and chronic kidney disease. Indeed, lowering
blood pressure is the most effective way to prevent stroke
and slow the progression of hypertensive renal disease [1].
Despite decades of intensive efforts to design and implement
methods to control blood pressure, 46% of US adults have
hypertension [2]. Globally, 31.1% of adults had hyperten-
sion, and the prevalence of hypertension is expected to
continue to rise [3]. Diuretics are one of the oldest and safest
classes of antihypertensive drugs. .iazide diuretics have
been used to treat hypertension for about 60 years [4] and
are associated with fewer side effects than other antihy-
pertensive agents [5]. .e average drop in blood pressure
(BP) in studies involving thiazide diuretics was 14.5/
6.7mmHg (systolic/diastolic) [6]. As a result, they are still
recommended as first-line agents by the European Society of
Cardiology, the American Society of Hypertension, and the
Eighth Joint National Committee [7]. Oryeongsan (ORS), a
traditional medicine used to regulate body fluids, has a long
history of use as a diuretic in Korea, China, and Japan [8]. In
animal experiments, ORS increases urine volume and so-
dium excretion [9]. Generally, all classes of diuretics have the
effect of lowering blood pressure by decreasing blood vol-
ume [10]. .us, it is predicted that ORS influence on blood
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pressure, but there are not many high-quality studies using
ORS for hypertension [11, 12]. .ere have been no reports
on the effect of ORS in SHR, except for one in China [13],
and the goal of this research is to investigate the effects of
ORS on hypertension and kidney damage in spontaneous
hypertensive rats (SHR).
2. Materials and Methods
2.1. Plant Materials and Preparation of ORS. .e medicinal
herbs required to formulate ORS were purchased from
Kwangmyungdang Medicinal Herbs Co. in Korea and au-
thenticated by the Department of Prescription, College of
Korean Medicine, Woosuk University. .e formula of ORS
was based on the Chinese Pharmacopoeia [8], and the
composition ratio is listed in Table 1. First, 1.6 kg of ORS was
extracted with 16 L of 30% ethanol at room temperature
(25°C) for 24 hours. .e ethanol extract was then filtered
through filter paper no. 2 (Advantec, Japan) and concen-
trated using a rotary evaporator (Eyela rotary evaporator
NE-2001, Japan) at 60°C. Finally, 225 g of ORS extract was
obtained by freeze-drying the concentrated ethanol extract
(Ilshin freeze dryer FD8508, Korea) at −75°C. .e constit-
uents of ORS were subsequently analyzed by the chro-
matographic fingerprint (see Supplementary Materials).
2.2. Animals and Experimental Protocol. .is study was
conducted in compliance with Good Laboratory Practice
(GLP) regulations and was approved by the KPC Labs In-
stitutional Animal Care and Use Committee (protocol
P172005). Male spontaneously hypertensive rats (SHR/
NCrlCrlj, SHR, 8 weeks old) were purchased from Charles
River Laboratories Japan, Inc. (Yokohama, Japan). .e rats
were individually housed in standard laboratory cages at
standard temperature (21–24°C), humidity (45–60%), and
lighting conditions (12 h light/dark) with free access to
rodent chow and water.
When they were 10 weeks old, the rats were distributed
into two groups according to systolic blood pressure (SBP)
and diastolic blood pressure (DBP), creating a similar av-
erage baseline blood pressure in both groups (Table 2). Each
treatment group had five rats. Rats were treated with 10mL/
kg vehicle (distilled water) or 200mg/kg ORS extract (at
20mg/mL) prepared by the method described above. Ve-
hicle and ORS extract were administered via oral gavage
once a day for 21 days.
At the end of 3 weeks, the rats were anesthetized with
isoflurane, and 10mL blood was collected from the ab-
dominal aorta (10mL SST tube, Vacutainer, BD, USA). .e
right kidneys were removed, and one slice of the middle
transverse section from each kidney was fixed in 10%
buffered formalin solution and then embedded in paraffin.
.e remaining portion of each kidney was stored at −70°C
until protein extraction.
2.3. Blood Pressure Measurement. Blood pressure was
measured on the 7th, 14th, and 21st day after the start of
treatment. Measurements of SBP and DBP were repeated
three times for each animal, and the mean value was
recorded. .e animals were allowed to rest for at least
15minutes at 30°C before blood pressure was measured.
Blood pressure was measured by a tail-cuff using a BP-2000
series II instrument (Visitech Systems, USA).
2.4. Hematological and Serum Biochemical Analysis.
Blood samples were centrifuged for 10 minutes at 6,000 rpm
at 4°C. Blood urea nitrogen (BUN) and creatinine (Cr) were
measured using DRI-CHEM-4000i (Fujifilm Co., Japan).
2.5. Histology. Paraffin-embedded kidneys were sectioned
into 4-μm thick sections and then stained with periodic acid-
Schiff and trichrome according to common methods.
Glomerular injury was measured by determining the scle-
rosis index [14]. Every glomerulus in each kidney section
was scored according to the extent of sclerosis (0, no scle-
rosis; 1, sclerosis of <25% of the glomerulus; 2, 25–50%; 3,
50–75%; 4, >75%), and the average of these scores was
considered the final sclerosis index for each kidney section.
Tubulointerstitial injury was evaluated by morphometric
analysis using ImageJ software (Version 1.51j8, National
Institutes of Health, Bethesda, MD, USA). Ten consecutive
digital images at 200x magnification were captured within
the cortex of each kidney. Images containing large arteries
were replaced with other images because periarterial fibrosis
might affect subsequent analysis. Software was used to
quantify the fibrotic area (bright blue in color after the
trichrome stain), and the fibrotic area percentage was cal-
culated for each kidney.
2.6. StatisticalAnalysis. Data collected during the study were
expressed as mean± SD. Statistical analysis was performed
with independent t-tests using SPSS 26.0 (IBM Co., USA).
Comparisons resulting in p values <0.05 were considered
significant.
3. Results
3.1. Effect of ORS on Blood Pressure. At the beginning of
treatment, the average SBP in the ORS-treated group and
vehicle-treated-control group (control) was similar
(194.7± 19.6 vs. 194.7± 17.9mmHg, respectively). One week
after treatment, the ORS-treated group showed a nonsig-
nificant trend toward a lower SBP (194.1± 18.3mmHg)
relative to control (209.0± 7.8mmHg). On the 2nd and 3rd
week after treatment, the ORS-treated group had signifi-
cantly lower SBP than control (191.3± 6.5 vs.
206.3± 9.8mmHg, respectively, p � 0.022 at 2nd week;
195.8± 7.8 vs. 217.0± 8.1mmHg, respectively, p � 0.003 at
3rd week). During the 2nd and 3rd week, the ORS-treated
group showed a trend toward lower DBP than the control
group, but there was no significant difference (Figure 1 and
Table 2).
3.2. Effect of Oryeongsan onRenal Function. BUN and serum
Cr at the time of sacrifice were not different between the
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ORS-treated group and the control group (BUN: 23.7± 1.1
vs. 22.7± 2.8mg/dL, respectively, p � 0.508; Cr: 19.0± 2.2 vs.
21.6± 2.1 μM, respectively, p � 0.083) (Figure 2).
3.3. Effect of ORS on the Development of Glomerulosclerosis
and Tubulointerstitial Fibrosis. .e glomerular sclerosis
index was generally very low in both groups (0.00± 0.0 in
ORS-treated group vs. 0.01± 0.01 in control, p � 0.127)
meaning that, in this animal model, hypertension did not
cause significant injury. However, the percentage of tissue
area with evidence of tubulointerstitial fibrosis was signifi-
cantly smaller in the ORS-treated group (1.68± 0.60) than in
the control group (3.17± 0.96, p � 0.019) (Figures 3 and 4).
4. Discussion
ORS is composed of five medicinal herbs, each of which is
known to have a diuretic or antihypertensive effect. In each
animal experiment, ethyl acetate and n-butanol, the major
components of A. orientale and P. cocos, were found to
increase urine volume and electrolyte excretion [15, 16]. In
addition, P. umbellatus extract increased urine volume and
electrolyte excretion by inhibiting the mRNA expression of
aquaporin 2 and vasopressin 2 receptors, which are involved
in resorption of water in the kidney [17]. A. macrocephala
also exhibited a diuretic effect by inhibiting the mRNA
expression of aquaporin 2 [18]. Cinnamaldehyde, a major
component of C. cassia, is related to blood pressure regu-
lation, and it exhibited a vasodilatory effect by inhibiting the
influx and release of Ca+ through an endothelial indepen-
dent pathway [19]. Studies using ORS in hypertension
models have been conducted in China and Japan. In stroke-
prone spontaneously hypertensive rats (SPSHR), feed mixed
with ORS was given to rats for 8weeks. ORS showed diuretic
effect by lowering the concentration of vasopressin in urine,
but did not show a significant change in urine volume and
blood pressure. However, since ORS used in this experiment





















































Figure 1: Changes in systolic and diastolic blood pressure of spontaneously hypertensive rats (SHR) treated with oryeongsan or vehicle
control for 3 weeks. Data are expressed as mean± SD. ∗p< 0.05 and ∗∗p< 0.01 compared with vehicle.
Table 1: Formulation for oryeongsan.
Herbal name Scientific name Weight ratio Origin
Alismatis Rhizoma Alisma orientale Juzepzuk 5.0 Korea
Poria Sclerotium Poria cocos Wolf 3.0 China
Atractylodis Rhizoma Atractylodes macrocephala Koidzumi 3.0 China
Polyporus Polyporus umbellatus Fries 3.0 China
Cinnamomi Cortex Cinnamomum cassia Presl 2.0 Vietnam
Table 2: Blood pressure of spontaneously hypertensive rats (SHR) treated with oryeongsan or vehicle control for the experimental period.
SBP (mmHg) DBP (mmHg)
Baseline Week 1 Week 2 Week 3 Baseline Week 1 Week 2 Week 3
Oryeongsan (n� 5) 194.7± 19.6 194.1± 18.3 191.3± 6.5∗ 195.8± 7.8∗∗ 120.9± 27.7 95.2± 38.2 106.6± 12.2 123.6± 26.2
Vehicle (n� 5) 194.7± 17.9 209.0± 14.9 206.3± 9.8 217.0± 8.1 121.3± 33.5 110.6± 27.9 131.1± 28.7 143.9± 29.2
.e results are expressed as mean± SD. ∗p< 0.05; ∗∗p< 0.01 compared to the values of vehicle-treated SHR. SBP, systolic blood pressure. DPB, diastolic blood
pressure.
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did not follow the composition ratio of the original pre-
scription, there were limitations to confirming the diuretic
and antihypertensive effects of ORS [20]. In the 2 kidney 1
clip (2K1C) model, rats were orally administered with
20–80 g/kg of ORS for 30 days every day, and an increase in




























Figure 2: Serum levels of blood urea nitrogen (BUN) and creatinine (Cr) at the time of sacrifice..ere was no significant difference between























Figure 3: Morphometric analysis of tubulointerstitial fibrosis in the kidney of spontaneous hypertensive rats (SHR) treated with oryeongsan





Figure 4: Representative kidney samples of spontaneously hypertensive rats (SHR) treated with oryeongsan (a) and vehicle (b). .e fibrotic
area of the renal cortex is stained in bright blue color (arrows).
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ORS-treated groups [21]. SHRs are a well-established model
of human essential hypertension and are characterized by a
progressive increase of blood pressure with age [22]. In the
present study, the ORS-treated group had significantly lower
SBP than control, suggesting that ORS helped manage blood
pressure in SHR. In previous studies in China, animals
treated daily with 4.8–19.2 g/kg of ORS for 8 weeks had
significantly lower SBP compared to control animals [13]..e
dose of ORS used in this study was 200mg/kg, indicating that
a lower dose of ORS is also effective in lowering blood
pressure. .e mechanism by which ORS lowers blood
pressure is currently unclear. In recent studies, ORS has been
shown to be associated with the renin-angiotensin-aldoste-
rone system (RAAS) [23]. In one study, ORS decreased
plasma renin activity and aldosterone concentrations and
induced diuresis by inhibiting the RAAS [9]. On the other
hand, it has been shown that ORS promotes diuresis by
blocking the sodium channel of the distal tubule in a manner
similar to thiazide diuretics [24]. .us, the antihypertensive
effects of ORS seem to be related to diuretic action, but further
research is needed to fully elucidate the mechanism. Serum
BUN and Cr levels of SHR were not different in ORS-treated
mice even after 3weeks of daily treatment. .is means that
even if the reduction in blood pressure occurred due to di-
uretic activity, there was likely no loss of renal function due to
dehydration. In studies conducted on hyperuricemic and
diabetic mice, treatment with ORS lowered serum BUN and
Cr levels and showed a renal protective effect [25, 26]. Hy-
pertensive nephrosclerosis is caused by damage to the renal
parenchyma due to high blood pressure and is typically as-
sociated with pathohistological changes in the renal vessels,
glomeruli, and interstitial tissues [27]. .e evaluation of renal
damage requires visual examination and computerized
morphological analysis by a trained pathologist [28]. Al-
though glomerulosclerosis was not observed in this study,
tubulointerstitial fibrosis was significantly inhibited in the
ORS-treated group. Tubulointerstitial fibrosis is a condition of
clinical concern because it leads to chronic renal failure in
most kidney diseases [14]. .e renal protective effects of ORS
have been confirmed in other studies, which have shown that
it suppresses the expansion of themesangial matrix in diabetic
rats [26, 29].
5. Conclusions
Together, our findings suggest that ORS is effective in re-
ducing SBP and ameliorating renal damage in SHR. Fur-
thermore, these studies provide new evidence supporting the
renal protective effects of ORS in SHR. Onemain limitation of
this study was that we could not determine whether ORS
acted via a diuretic effect. Future research should clarify the
mechanisms by which ORS lowers blood pressure and should
directly compare its effects against other diuretic agents.
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